Researchers from Peptidream Inc. presented preclinical characterization of novel carbonic anhydrase IX (CAIX)-targeting radiopeptides, [64Cu]PD-32766 and [177Lu]PD-32766, being developed for the diagnosis and treatment of clear cell renal cell carcinoma (ccRCC), respectively.
Jeil Pharmaceutical Co. Ltd. has identified son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of cancer.
Kurome Therapeutics Inc. along with the Cincinnati Children’s Hospital Medical Center and U.S. Department of Health and Human Services have patented interleukin-1 receptor-associated kinase (IRAK) and/or FLT3 (FLK2/STK1) inhibitors reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders.
Researchers from Egle Therapeutics SAS presented the discovery of a novel immunocytokine, EGL-001, designed to selectively target tumor-infiltrating regulatory T cells (Tregs).
RNA-binding proteins (RBPs) have emerged as interesting targets for cancer therapy. There is growing evidence that RBPs are dysregulated in cancer, usually with abnormal expression and/or with the presence of mutations.
Context Therapeutics Inc. has received FDA clearance of its IND application for CTIM-76, a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody.
The TEAD family of transcription factors are regulated by the Hippo tumor suppressor pathway and they act by binding the co-activators YAP and TAZ that drive the transcription of genes involved in cell survival, proliferation, migration, differentiation and resistance.
Radionetics Oncology Inc. has discovered drugs targeting follicle-stimulating hormone (FSH) receptors reported to be useful for the diagnosis and treatment of cancer.
RSS
